Hepatitis B (HBVD) Algorithm for Chronic Renal Disease
Revision Date: May 3, 2019

Hepatitis B – HBVD for Dialysis
(for Chronic Renal Disease)

First series (3 doses) HBVD

Test for antiHBs 1 to 6 months after primary series of hepatitis B vaccine.

- AntiHBs Positive
  - Retest annually

- AntiHBs Negative
  - Administer second series
    - Retest antiHBs 1 month later
      - AntiHBs Positive
        - Retest annually
      - AntiHBs Negative
        - Administer one dose
          - Retest annually

Annual retest

- AntiHBs Positive
  - Retest annually

- AntiHBs Negative
  - Administer one dose
    - Retest annually

STOP

Non-responder. No further hepatitis B vaccine indicated.*

Individuals with chronic renal disease who have responded initially to hepatitis B vaccine are recommended to receive a booster dose if anti-HBs are negative on annual testing. (CIG 2017)

Available data do not suggest a maximum number of booster doses. (MMWR 2018)

Anti-HBs testing 1–2 months following the booster dose to assess response is not recommended. (MMWR 2018)

Individuals who fail to respond to 3 additional doses of vaccine are unlikely to benefit from further immunization and should be counselled on alternative risk reduction measures. (CIG 2017)

*Annual retesting of non-responders is not recommended. Follow post exposure recommendations in event of bloodborne pathogen exposure.

- Individuals who received standard dose hepatitis B vaccine prior to developing chronic renal disease, who subsequently develop chronic renal disease and are determined to be non-immune should receive a series of HBVD. If non-immune after the HBVD series they should be considered a non-responder.

- In the event individuals received standard dose Hepatitis B vaccine after developing chronic renal disease and are determined to be non-immune, the standard dose hepatitis B vaccine series should NOT be considered valid.